AVIR Atea Pharmaceuticals initiates first-in-human phase 1 clinical trial of at-587 for the treatment of hepatitis e virus
AVIR Atea Pharmaceuticals initiates first-in-human phase 1 clinical trial of at-587 for the treatment of hepatitis e virus
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.